# Eli Lilly vs Merck & Co: stocks compared

URL: https://funkfolio.com/compare/lly-vs-mrk

> Eli Lilly ($1.26T, P/E 45.9) and Merck & Co ($353.4B, P/E 145) compared: size, valuation, margins, debt, cash and price change.

---

## Eli Lilly vs Merck & Co

Eli Lilly (LLY), health care, and Merck & Co (MRK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Eli Lilly is worth $1.26T on the stock market and Merck & Co $353.4B: Eli Lilly is valued at 3.6 times as much. Eli Lilly trades at 45.9 times earnings and Merck & Co at 145. Over the past year Eli Lilly's share price has moved +39.0% and Merck & Co's +49.8%.

### Key facts

- **Eli Lilly market value:** $1.26T
- **Merck & Co market value:** $353.4B
- **Eli Lilly P/E:** 45.9
- **Merck & Co P/E:** 145
- **Eli Lilly revenue:** $65.2B FY to 2025-12-31
- **Merck & Co revenue:** $65B FY to 2025-12-31
- **Superinvestors holding both:** 12

Market values as of 18 Nov 2026, 06:57 UTC.

Eli Lilly vs Merck & Co: every measure side by side

| Measure | Eli Lilly | Merck & Co |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | United States |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $1.26T higher | $353.4B lower |
| Revenue | $65.2B higher | $65B lower |
| Earnings | $20.6B higher | $18.3B lower |
| Employees | 50,000 lower | 73,000 higher |
| Total assets | $112.5B lower | $136.9B higher |
| Valuation |  |  |
| P/E | 45.9 lower | 145 higher |
| P/S | 19.3 higher | 5.4 lower |
| P/B | 31.3 higher | 7.9 lower |
| Dividend yield | 0.47% lower | 2.33% higher |
| Profitability |  |  |
| Operating margin | — | — |
| Balance sheet |  |  |
| Net assets | $26.5B lower | $52.6B higher |
| Total liabilities | $85.9B higher | $84.2B lower |
| Total debt | $42.5B lower | $49.3B higher |
| Cash on hand | $7.3B lower | $14.6B higher |
| Price change |  |  |
| Today | -1.13% lower | -0.75% higher |
| 1 year | +39.0% lower | +49.8% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Eli Lilly 138.5, Merck & Co 154.4.

- Eli Lilly (LLY)
- Merck & Co (MRK)

Eli Lilly and Merck & Co share prices over one year, rebased to 100: Eli Lilly ends at 138.5, Merck & Co at 154.4.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | LLY | MRK |
| --- | --- | --- |
| Nov 28, 2025 | 105.3 | 112.9 |
| Dec 31, 2025 | 105.2 | 113.4 |
| Jan 30, 2026 | 101.5 | 118.7 |
| Feb 27, 2026 | 103.0 | 133.3 |
| Mar 31, 2026 | 90.0 | 129.5 |
| Apr 30, 2026 | 91.5 | 117.6 |
| May 29, 2026 | 108.2 | 127.8 |
| Jun 30, 2026 | 117.4 | 138.4 |
| Jul 31, 2026 | 112.4 | 140.2 |
| Aug 31, 2026 | 113.2 | 159.1 |
| Sep 30, 2026 | 113.3 | 156.5 |
| Oct 30, 2026 | 138.7 | 161.0 |
| Nov 17, 2026 | 138.5 | 154.4 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (12)

- [Mairs & Power team](https://funkfolio.com/gurus/mairs-and-power) 3.4% / 0.1%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 1.9% / 1.6%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 1.8% / 1.7%
- [Rajiv Jain](https://funkfolio.com/gurus/rajiv-jain) 1.6% / &lt;0.1%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.7% / 0.1%
- [Temasek](https://funkfolio.com/gurus/temasek) 0.5% / 0.3%
- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 0.5% / 0.2%
- [Cliff Asness](https://funkfolio.com/gurus/cliff-asness) 0.4% / 0.4%
- [David Shaw (founder)](https://funkfolio.com/gurus/david-shaw) 0.4% / 0.2%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) 0.1% / 0.1%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) &lt;0.1% / &lt;0.1%
- [Bill Nygren](https://funkfolio.com/gurus/bill-nygren) &lt;0.1% / 2.1%

#### Eli Lilly only (16)

- [Primecap team](https://funkfolio.com/gurus/primecap) 6.5%
- [Polen Capital team](https://funkfolio.com/gurus/polen-capital) 4.6%
- [Jensen team](https://funkfolio.com/gurus/jensen-investment) 4.0%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 1.4%
- [Cathie Wood](https://funkfolio.com/gurus/cathie-wood) 0.7%
- [Jeffrey Altman](https://funkfolio.com/gurus/jeffrey-altman) 0.6%
- [Ray Dalio (founder)](https://funkfolio.com/gurus/bridgewater) 0.4%
- [George Soros](https://funkfolio.com/gurus/george-soros) 0.4%
- [Stanley Druckenmiller](https://funkfolio.com/gurus/stanley-druckenmiller) 0.3%
- [Mario Gabelli](https://funkfolio.com/gurus/mario-gabelli) 0.3%
- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.3%
- [Frank Sands](https://funkfolio.com/gurus/frank-sands) 0.2%
- [Ron Baron](https://funkfolio.com/gurus/ron-baron) 0.2%
- [Paul Tudor Jones](https://funkfolio.com/gurus/paul-tudor-jones) 0.2%
- [Israel Englander](https://funkfolio.com/gurus/israel-englander) 0.1%
- [Rob Citrone](https://funkfolio.com/gurus/rob-citrone) 0.1%

#### Merck & Co only (11)

- [Bill Smead](https://funkfolio.com/gurus/bill-smead) 7.1%
- [Thomas Kahn](https://funkfolio.com/gurus/thomas-kahn) 4.9%
- [Howard Gleicher](https://funkfolio.com/gurus/howard-gleicher) 2.0%
- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 1.5%
- [Josef Lakonishok](https://funkfolio.com/gurus/josef-lakonishok) 1.4%
- [Prem Watsa](https://funkfolio.com/gurus/prem-watsa) 0.9%
- [Christopher Bloomstran](https://funkfolio.com/gurus/christopher-bloomstran) 0.6%
- [Sarah Ketterer](https://funkfolio.com/gurus/sarah-ketterer) 0.6%
- [Mark Boyar](https://funkfolio.com/gurus/mark-boyar) 0.5%
- [Joel Greenblatt](https://funkfolio.com/gurus/joel-greenblatt) 0.2%
- [Thomas Russo](https://funkfolio.com/gurus/thomas-russo) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Eli Lilly / Merck & Co). [Who owns LLY](https://funkfolio.com/stock/LLY/superinvestors) · [Who owns MRK](https://funkfolio.com/stock/MRK/superinvestors)

### More on Eli Lilly

- [Eli Lilly (LLY) stock page](https://funkfolio.com/stock/LLY)
- [Eli Lilly market cap](https://funkfolio.com/stock/LLY/market-cap)
- [Eli Lilly revenue](https://funkfolio.com/stock/LLY/revenue)
- [Eli Lilly P/E ratio](https://funkfolio.com/stock/LLY/pe-ratio)
- [Eli Lilly operating margin](https://funkfolio.com/stock/LLY/operating-margin)
- [Eli Lilly total debt](https://funkfolio.com/stock/LLY/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Merck & Co

- [Merck & Co (MRK) stock page](https://funkfolio.com/stock/MRK)
- [Merck & Co market cap](https://funkfolio.com/stock/MRK/market-cap)
- [Merck & Co revenue](https://funkfolio.com/stock/MRK/revenue)
- [Merck & Co P/E ratio](https://funkfolio.com/stock/MRK/pe-ratio)
- [Merck & Co operating margin](https://funkfolio.com/stock/MRK/operating-margin)
- [Merck & Co total debt](https://funkfolio.com/stock/MRK/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Eli Lilly against its closest peers

- [Eli Lilly vs Johnson & Johnson](https://funkfolio.com/compare/jnj-vs-lly)
- [Eli Lilly vs AbbVie](https://funkfolio.com/compare/abbv-vs-lly)
- [Eli Lilly vs UnitedHealth Group](https://funkfolio.com/compare/lly-vs-unh)

#### Merck & Co against its closest peers

- [Merck & Co vs UnitedHealth Group](https://funkfolio.com/compare/mrk-vs-unh)
- [Merck & Co vs Novartis](https://funkfolio.com/compare/mrk-vs-nvs)
- [Merck & Co vs AbbVie](https://funkfolio.com/compare/abbv-vs-mrk)
- [Merck & Co vs AstraZeneca](https://funkfolio.com/compare/azn-vs-mrk)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Eli Lilly or Merck & Co?**

By market value, Eli Lilly is the larger: $1.26T against $353.4B for Merck & Co. By revenue in its latest fiscal year, Eli Lilly is the larger: $65.2B against $65B for Merck & Co.

**Which has the higher P/E ratio?**

Merck & Co: 145, against 45.9 for Eli Lilly. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher dividend yield?**

Merck & Co: 2.33%, against 0.47% for Eli Lilly. Dividend yield is the last twelve months' dividends as a share of today's share price.

**Which has more debt?**

Merck & Co: $49.3B, against $42.5B for Eli Lilly. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Eli Lilly and Merck & Co?**

In their latest 13F filings, Mairs & Power team, Jeremy Grantham (co-founder), Ken Fisher, Rajiv Jain, Ken Griffin, Temasek, Brandon Haley, Cliff Asness, David Shaw (founder), Murray Stahl, Dodge & Cox team and Bill Nygren hold both.

### Cite this page

Funkfolio, “Eli Lilly vs Merck & Co”, data as of 18 November 2026. https://funkfolio.com/compare/lly-vs-mrk

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
